A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity

Annals of Neurology

Volumn 78, Issue 1, 2015, Pages 115-127

  Esposito, Federica ^a,b   Sorosina, Melissa ^b   Ottoboni, Linda ^c   Lim, Elaine T ^c,d   Replogle, Joseph M ^c,e   Raj, Towfique ^c,e   Brambilla, Paola ^b   Liberatore, Giuseppe ^a   Guaschino, Clara ^a   Romeo, Marzia ^a   Pertel, Thomas ^c,d   Stankiewicz, James M ^c,d   Martinelli, Vittorio ^a,b   Rodegher, Mariaemma ^a,b   Weiner, Howard L ^c,d   Brassat, David ^f   Benoist, Christophe ^d,e   Patsopoulos, Nikolaos A ^c,d,e   Comi, Giancarlo ^a,b   Elyaman, Wassim ^c,d   Martinelli Boneschi, Filippo ^a,b   De Jager, Philip L ^c,d,e   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Obstetrics and Gynaecology Department   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GAMMA INTERFERON; INTERFERON BETA SERINE; SODIUM PROTON EXCHANGE PROTEIN; BETA INTERFERON; CYTOKINE; IMMUNOLOGICAL ADJUVANT; SLC9A9 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC9A9 GENE; T LYMPHOCYTE; TREATMENT RESPONSE; CELL CULTURE; CELL DIFFERENTIATION; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENE SILENCING; GENETICS; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CELL DIFFERENTIATION; CELLS, CULTURED; COHORT STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; IN VITRO TECHNIQUES; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RNA, SMALL INTERFERING; SODIUM-HYDROGEN ANTIPORTER; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84933180140     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24429     Document Type: Article

References (33)

1. Killestein J, Polman CH,. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011; 7: 221-228.
2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504.
3. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
4. Jacobs LD, Cookfair DL, Rudick RA, et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
5. Rio J, Comabella M, Montalban X,. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009; 5: 553-560.
6. Cohen JA, Barkhof F, Comi G, et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
7. Polman CH, O'Connor PW, Havrdova E, et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
8. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, et al., Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
9. McDonald WI, Compston A, Edan G, et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
10. Romeo M, Martinelli-Boneschi F, Rodegher M, et al., Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Eur J Neurol 2013; 20: 1060-1067.
11. Price AL, Patterson NJ, Plenge RM, et al., Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
12. De Jager PL, Jia X, Wang J, et al., Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.
13. Purcell S, Neale B, Todd-Brown K, et al., PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
14. Devlin B, Roeder K,. Genomic control for association studies. Biometrics 1999; 55: 997-1004.
15. Mantel N, Haenszel W,. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
16. Raj T, Rothamel K, Mostafavi S, et al., Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 2014; 344: 519-523.
17. Ottoboni L, Keenan BT, Tamayo P, et al., An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med 2012; 4: 153ra131.
18. Gauthier SA, Mandel M, Guttmann CR, et al., Predicting short-term disability in multiple sclerosis. Neurology 2007; 68: 2059-2065.
19. Du P, Kibbe WA, Lin SM,. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547-1548.
20. Goertsches RH, Hecker M, Koczan D, et al., Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010; 11: 147-161.
21. Malhotra S, Bustamante MF, Perez-Miralles F, et al., Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis. PLoS One 2011; 6: e23634.
22. Beriou G, Bradshaw EM, Lozano E, et al., TGF-beta induces IL-9 production from human Th17 cells. J Immunol 2010; 185: 46-54.
23. Byun E, Caillier SJ, Montalban X, et al., Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344.
24. Comabella M, Craig DW, Morcillo-Suarez C, et al., Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972-978.
25. Pappas DJ, Oksenberg JR,. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology 2010; 74 (suppl 1): S62-S69.
26. De Jager PL, Chibnik LB, Cui J, et al., Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009; 8: 1111-1119.
27. Gourraud PA, McElroy JP, Caillier SJ, et al., Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol 2011; 69: 65-74.
28. Nakamura N, Tanaka S, Teko Y, et al., Four Na+/H+ exchanger isoforms are distributed to Golgi and post-Golgi compartments and are involved in organelle pH regulation. J Biol Chem 2005; 280: 1561-1572.
29. Ohgaki R, van IJzendoorn SC, Matsushita M, et al., Organellar Na+/H+ exchangers: novel players in organelle pH regulation and their emerging functions. Biochemistry 2011; 50: 443-450.
30. Kondapalli KC, Hack A, Schushan M, et al., Functional evaluation of autism-associated mutations in NHE9. Nat Commun 2013; 4: 2510.
31. Rivinoja A, Hassinen A, Kokkonen N, et al., Elevated Golgi pH impairs terminal N-glycosylation by inducing mislocalization of Golgi glycosyltransferases. J Cell Physiol 2009; 220: 144-154.
32. Mkhikian H, Grigorian A, Li CF, et al., Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun 2011; 2: 334.
33. Huffman JE, Knezevic A, Vitart V, et al., Polymorphisms in B3GAT1, SLC9A9 and MGAT5 are associated with variation within the human plasma N-glycome of 3533 European adults. Hum Mol Genet 2011; 20: 5000-5011.